The Hypoparathyroidism Genetic Testing program is a sponsored, no-charge genetic testing and counseling program for patients with an established diagnosis of non-surgical hypoparathyroidism. The Hypoparathyroidism Genetic Testing program is intended to build knowledge about the genetic causes of hypoparathyroidism and support clinical management so that individuals and their providers can make more informed decisions about their health. A few notes about this program:
If you don’t find answers with your initial order,
Hypoparathyroidism Genetic Testing Program includes one re-requisition within 90 days to re-test genes within the original clinical area.
Simply log into your account, navigate to the order, and click "Add rerequisition”
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website.
Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Calcilytix's product candidate, encaleret, is an investigational orally-administered small molecule designed to inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and urine calcium.
Calcilytix is led by a team of industry veterans who have been responsible for developing over 30 molecules through Initial New Drug (IND) applications and more than 10 approved drugs. Together with physicians and patients, Calcilytix aims to develop a safe and effective treatment option for patients with hypoparathyroidism and autosomal dominant hypocalcemia type 1 (ADH1).